|Bid||2.10 x 1400|
|Ask||2.11 x 3400|
|Day's range||2.04 - 2.19|
|52-week range||0.74 - 2.55|
|PE ratio (TTM)||N/A|
|Earnings date||8 May 2018 - 14 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.37|
On a per-share basis, the Cupertino, California-based company said it had net income of 5 cents. The specialty pharmaceutical company posted revenue of $19.5 million in the period, which topped Street ...
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. In an Oct. 2 press release, ...
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. With (Other OTC: WWTH - news) intense competition and pricing pressure eroding sales of medicines for diabetes, rheumatoid arthritis and other lucrative disease categories, and an already crowded field for developmental cancer drugs, big pharma sees NASH as an enormous new market for future profit that will accelerate a wave of deal making. Bristol-Myers Squibb also confirmed it is looking for additional assets to enhance its internally-developed NASH drugs.